NeuBase Therapeutics Inc logo

NeuBase Therapeutics Inc

$ 0.38 -0.019 (-4.76%) 11:31 AM EST
P/E:
At Loss
P/B:
0.40
Market Cap:
$ 12.26M
Enterprise V:
$ -11.24M
Volume:
36.75K
Avg Vol (2M):
85.35K
Also Trade In:
Volume:
36.75K
Market Cap $:
12.26M
PE Ratio:
At Loss
Avg Vol (2-Month):
85.35K
Enterprise Value $:
-11.24M
PB Ratio:
0.40
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.
Name Current Vs Industry Vs History
Cash-To-Debt 4.85
Equity-to-Asset 0.76
Debt-to-Equity 0.2
Debt-to-EBITDA -0.19
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 31.3
3-Year EPS without NRI Growth Rate 41.3
3-Year FCF Growth Rate 39.5
Name Current Vs Industry Vs History
5-Day RSI 31.38
9-Day RSI 25.64
14-Day RSI 25.36
6-1 Month Momentum % -67.88
12-1 Month Momentum % -82.34

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 7.53
Quick Ratio 7.53
Cash Ratio 7.1

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -126.1
Name Current Vs Industry Vs History
ROE % -72.41
ROA % -59.61
ROIC % -320.36
ROC (Joel Greenblatt) % -401.43
ROCE % -64.31

Financials (Next Earnings Date:2022-12-23 Est.)

NBSE's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:NBSE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -1.01
Beta 0.99
Volatility % 78.99
14-Day RSI 25.36
14-Day ATR ($) 0.060119
20-Day SMA ($) 0.48511
12-1 Month Momentum % -82.34
52-Week Range ($) 0.3777 - 4.4
Shares Outstanding (Mil) 32.26

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

NeuBase Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

NeuBase Therapeutics Inc Analysis

Share your research

Headlines

See More
No news.